Antidepressants and sleep: A qualitative review of the literature

Drugs

Volumn 65, Issue 7, 2005, Pages 927-947

  Wilson, Sue ^a   Argyropoulos, Spilios ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; REBOXETINE; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

BRUXISM; DEPRESSION; ELECTROENCEPHALOGRAM; EYE MOVEMENT DISORDER; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; QUALITATIVE ANALYSIS; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SEROTONIN RELEASE; SLEEP; SLEEP DISORDER; SLEEP PATTERN; STATISTICAL SIGNIFICANCE;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP STAGES;

EID: 18644386303     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565070-00003     Document Type: Review

References (151)

1. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999; 60 Suppl. 17: 28-31
2. Lauer CJ, Schreiber W, Holsboer F, et al. In quest of identifiying vulnerability markers for psychiatric disorders by all-night polysomnography. Arch Gen Psychiatry 1995; 52: 145-52
3. Thase ME, Buysse DJ, Frank E, et al. Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. Am J Psychiatry 1997; 154 (4): 502-9
4. Wilson SJ, Bailey JE, Alford C, et al. Effects of 5 weeks of administration of fluoxetine and dothiepin in normal volunteers on sleep, daytime sedation, psychomotor performance and mood. J Psychopharmacol 2002; 16 (4): 321-31
5. Wilson SJ, Bailey JE, Rich AS, et al. Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram. Eur Neuropsychopharmacol 2004; 14 (5): 367-72
6. Bell C, Wilson S, Rich A. Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers. Psychopharmacology Berl 2003; 166 (2): 102-10
7. Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283 (3): 1305-22
8. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994; 114 (4): 559-65
9. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984; 230 (1): 94-102
10. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340 (2-3): 249-58
11. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52 (12): 1023-9
12. Claassen V, Davies JE, Hertting G, et al. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol 1977; 60 (4): 505-16
13. Millan MJ, Gobert A, Lejeune F, et al. S33005, a novel ligand at both serotonin and norepinephrine transporters. I: receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 2001; 298 (2): 565-80
14. Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 2000; 12 (3): 1079-95
15. Moore P, Gillin C, Bhatti T, et al. Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry 1998; 55 (6): 534-9
16. Landolt HP, Kelsoe JR, Rapaport MH, et al. Rapid tryptophan depletion reverses phenelzine-induced suppression of REM sleep. J Sleep Res 2003; 12 (1): 13-8
17. Saletu B, Frey R, Krupka M, et al. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 1991; 14 (5): 439-47
18. Vasar V, Appelberg B, Rimon R, et al. The effect of fluoxetine on sleep: a longitudinal double blind polysomnographic study of healthy volunteers. Int Clin Psychopharmacol 1994; 9: 203-6
19. Feige B, Voderholzer U, Riemann D, et al. Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology 2002; 26 (2): 246-58
20. Nicholson AN, Pascoe PA. Studies on the modulation of the sleep-wakefulness continuum in man by fluoxetine, a 5HT uptake inhibitor. Neuropharmacology 1988; 27: 597-602
21. Winokur A, DeMartinis III NA, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. Clin Psychiatry 2003; 64 (10): 1224-9
22. Trivedi MH, Rush AJ, Armitage R, et al. Effects of fluoxetine on the polysomnogram in outpatients with major depression. Neuropsychopharmacology 1999; 20 (5): 447-59
23. Hendrickse WA, Roffwang HP, Granneman BD, et al. The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study. Neropsychopharmacology 1994; 10: 85-91
24. Rush AJ, Armitage R, Gillin JC, et al. Comparative effects of nefazodone and fluoxetine: on sleep in outpatients with major depressive disorder. Biol Psychiatry 1998; 44 (1): 3-14
25. Sharpley AL, Williamson DJ, Attenburrow ME, et al. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl) 1996; 126 (1): 50-4
26. Oswald I, Adam K. Effects of paroxetine on human sleep. Br J Clin Pharmacol 1986; 22 (1): 97-9
27. Schlosser R, Roschke J, Rossbach W, et al. Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers. Eur Neuropsychopharmacol 1998; 8 (4): 273-8
28. Wilson SJ, Bailey JE, Alford C, et al. Sleep and daytime sleepiness the next day following single nighttime dose of fluvoxamine, dothiepin End placebo in normal volunteers. J Psychopharmacology 2000; 14: 378-86
29. Hartmann E, Spinweber C, Fluvoxamine, a serotonin reuptake blocker: effects on sleep. J Sleep Res 1979; 8: 98
30. Jindal RD, Friedman ES, Berman SR, et al. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol 2003; 23 (6): 540-8
31. Hicks JA, Argyropoulos SV, Rich AS, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 2002 Jun; 180: 528-35
32. Kupfer DJ, Perel JM, Pollock BG, et al. Fluvoxamine versus desipramine: comparative polysomnographic effects. Biol Psychiatry 1991; 29: 33-10
33. Wilson SJ, Bell C, Coupland N, et al. Sleep changes during long-term treatment of depression with fluvoxamine: a home based study. Psychopharmacology 2000; 149: 360-5
34. van Bemmel AL, van den Hoofdakker RH, Beersma DGM, et al. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology 1993; 113: 225-30
35. Staner L, Kerkhofs M, De roux D, et al. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 1995; 18 (6): 470-7
36. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997 58 (8): 348-50
37. Luthringer R, Toussaint M, Schaltenbrand N, et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine: on sleep in inpatients with major depression. Psychopharmacol Bull 1996; 32 (4): 637-46
38. Farina B, Della Marca G, Mennuni G, et al. The effects of reboxetine on human sleep architecture in depression: preliminary results. J Affect Disord 2002; 71 (1-3): 273-5
39. Dunleavy DL, Brezinova V, Oswald I, et al. Changes during weeks in effects of tricyclic drugs on the human sleeping brain. Br J Psychiatry 1972; 120 (559): 663-72
40. Hochli D, Riemann D, Zulley J, et al. Is there a relationship between response to total sleep deprivation and efficacy of clomipramine treatment in depressed patients? Acta Psychiatr Scand 1986; 74 (2): 190-2
41. Jobert M, Jahnig P, Schulz H. Effect of two antidepressants on REM sleep and EMG activity during sleep. Neuropsychobiology 1999; 39 (2): 101-9
42. Shipley JE, Kupfer DJ, Griffin SJ, et al. Comparison of effects of desipramine and amitriptyline on EEG sleep of depressed patients. Psychopharmacology (Berl) 1985; 85 (1): 14-22
43. Ware JC, Brown FW, Moorad Jr PJ, et al. Effects on sleep: a double-blind study comparing trimipramine to imipramine in depressed insomniac patients. Sleep 1989; 12 (6): 537-49
44. Shain BN, Naylor M, Shipley JE, et al. Imipramine effects on sleep in depressed adolescents: a preliminary report. Biol Psychiatry 1990; 28 (5): 459-62
45. Mendlewicz J, Kempenaers C, de Maertelaer V. Sleep EEG and amitryptiline treatment in depressed inpatients. Biol Psychiatry 1991; 30(7): 691-702
46. Gillin JC, Wyatt RJ, Fram D, et al. The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline. Psychopharmacology (Berl) 1978; 59 (3): 267-72
47. Herdman JR, Cowen PJ, Campling GM, et al. Effect of lofepramine on 5-HT function and sleep. J Affect Disord 1993; 29 (1): 63-72
48. Nicholson AN, Pascoe PA, Turner C. Modulation of sleep by trimipramine in man. Eur J Clin Pharmacol 1989; 37 (2): 145-50
49. Akindele MO, Evans JI, Oswald I. Mono-amine oxidase inhibitors, sleep and mood. Electroencephalogr Clin Neurophysiol 1970; 29 (1): 47-56
50. Wyatt RJ, Fram DH, Kupfer DJ, et al. Total prolonged drug-induced REM sleep suppression in anxious-depressed patients. Arch Gen Psychiatry 1971; 24 (2): 145-55
51. Landolt HP, Raimo EB, Schnierow BJ, et al. Sleep and sleep electroencephalogram in depressed patients treated with phenelzine. Arch Gen Psychiatry 2001; 58 (3): 268-76
52. Blois R, Gaillard JM. Effects of moclobemide on sleep in healthy human subjects. Acta Psychiatr Scand Suppl 1990; 360: 73-5
53. Monti JM, Alterwain P, Monti D. The effects of moclobemide on nocturnal sleep of depressed patients. J Affect Disord 1990; 20 (3): 201-8
54. Steiger A, Benkert O, Holsboer F. Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men. Neuropsychobiology 1994; 30 (2-3): 101-5
55. Maeda Y, Hayashi T, Furuta H, et al. Effects of mianserin on human sleep. Neuropsychobiology 1990; 24 (4): 198-204
56. Nicholson AN, Pascoe PA, Stone BM. Modulation of catecholamine transmission and sleep in man. Neuropharmacology 1986; 25 (3): 271-4
57. Tormey WP, Buckley MP, O'Kelly DA, et al. Sleep-endocrine profile of the antidepressant mianserin. Curr Med Res Opin 1980; 6 (7): 456-60
58. Mendlewicz J, Dunbar GC, Hoffman G. Changes in sleep EEG architecture during the treatment of depressed patients with mianserin. Acta Psychiatr Scand Suppl 1985; 320: 26-9
59. Asian S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002; 25 (6): 677-9
60. Ruigt GS, Kemp B, Groenhout CM, et al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990; 38 (6): 551-4
61. Schittecatte M, Dumont F, Machowski R, et al. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002; 46 (4): 197-201
62. Sharpley AL, Walsh AE, Cowen PJ. Nefazodone - a novel antidepressant - may increase REM sleep. Biol Psychiatry 1992; 31 (10): 1070-3
63. Ware JC, Rose FV, McBrayer RH. The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep 1994; 17 (6): 544-50
64. Vogel G, Cohen J, Mullis D, et al. Nefazodone and REM sleep: how do antidepressants decrease REM sleep? Sleep 1998; 21 (1): 70-7
65. Ware JC, Pittard JT. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. J Clin Psychiatry 1990; 51 Suppl.: 18-22
66. Suzuki H, Yamadera H, Nakamura S, et al. Effects of trazodone and imipramine on the biological rhythm: an analysis of sleep EEG and body core temperature. J Nippon Med Sch 2002; 69 (4): 333-41
67. Yamadera H, Nakamura S, Suzuki H, et al. Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry Clin Neurosci 1998; 52 (4): 439-43
68. van Bemmel AL, Havermans RG, van Diest R. Effects of trazodone on EEG sleep and clinical state in major depression. Psychopharmacology (Berl) 1992; 107 (4): 569-74
69. Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990; 51 Suppl.: 13-7
70. Mouret J, Lemoine P, Minuit MP, et al. Effects of trazodone on the sleep of depressed subjects: a polygraphic study. Psychopharmacology (Berl) 1988; 95 Suppl.: S37-43
71. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26 (2): 249-60
72. Ott GE, Rao U, Lin KM, et al. Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response. Int J Neuropsychopharmacol. Epub 2004 Apr 26
73. Ott GE, Rao U, Nuccio I, et al. Effect of bupropion-SR on REM sleep: relationship to antidepressant response. Psychopharmacology (Berl) 2002; 165 (1): 29-36
74. Evans L, Golshan S, Kelsoe J, et al. Effects of rapid tryptophan depletion on sleep electroencephalogram and mood in subjects with partially remitted depression on bupropion. Neuropsychopharmacology 2002; 27 (6): 1016-26
75. Nofzinger EA, Reynolds III CF, Thase ME, et al. REM sleep enhancement by bupropion in depressed men. Am J Psychiatry 1995; 152 (2): 274-6
76. Ferini-Strambi L, Manconi M, Castronovo V, et al. Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia. J Psychopharmacol 2004; 18 (3): 417-22
77. DeVane CL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Moll Neurobiol 1999; 19 (4): 443-66
78. Monaca C, Boutrel B, Hen R, et al. 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 2003; 28 (5): 850-6
79. Gillin JC, Jernajczyk W, Valladares-Neto DC, et al. Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers. Psychopharmacology (Berl) 1994; 116 (4): 433-6
80. Wilson SJ, Bailey JE, Rich AS. The use of sleep measures to compare a new 5HT1A agonist eptapirone with buspirone in humans. J Psychopharmacol. In Press
81. Lawlor BA, Newhouse PA, Balkin TJ, et al. A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers. Biol Psychiatry 1991; 29 (3): 281-6
82. Riemann D, Voderholzer U, Cohrs S, et al. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 2002; 35: 165-74
83. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003; 4 (2): 121-30
84. Sharpley AL, Vassallo CM, Cowen PJ. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo. Biol Psychiatry 2000; 47 (5): 468-70
85. Urichuk LJ, Allison K, Holt A, et al. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration. J Affect Disord 2000; 58 (2): 135-44
86. de Boer T, Nefkens F, van Helvoirt A, et al. Differences in the modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996; 277: 852-60
87. Wilson SJ, Glue P, Nutt DJ. The effects of the α-2-adrenoceptor antagonist idazoxan on sleep in normal volunteers. J Psychopharmacol 1991; 5: 105-10
88. Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long term actions of mirtazapine. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 11-7
89. Chalon S, Pereira A, Lainey E, et al. Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology (Berl) 2005; 177 (4): 357-65
90. Lemoine P, Faivre T. Subjective and polysomnographic effects of milnacipran on sleep in depressed patients. Hum Psychopharmacol 2004; 19 (5): 299-303
91. Borbely AA. A two process model of sleep regulation. Hum Neurobiol 1982; 1 (3): 195-204
92. Ehlers CL, Havstad JW, Kupfer DJ. Estimation of the time course of slow-wave sleep over the night in depressed patients: effects of clomipramine and clinical response. Biol Psychiatry 1996; 39 (3): 171-81
93. Veitch W, Wilson SJ, Argyropoulos S, et al. Slow waves in sleep are altered by paroxetine and nefazodone in depressed patients [abstract]. J Psychopharm 2001; 15 (3 Suppl.): A18
94. Sateia MJ, Doghramji K, Hauri PJ, et al. Evaluation of chronic insomnia: an American Academy of Sleep Medicine review. Sleep 2000; 23: 243-308
95. Parrott AC, Hindmarch I. Factor analysis of a sleep evaluation questionnaire. Psychol Med 1978; 8: 325-9
96. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations: a review. Psychopharmacology (Berl) 1980; 71: 173-9
97. Zisapel N, Laudon M. Subjective assessment of the effects of CNS-active drugs on sleep by the Leeds Sleep Evaluation Questionnaire: a review. Hum Psychopharmacol 2003; 18: 1-20
98. Ware JC. Tricyclic antidepressants in the treatment of insomnia. J Clin Psychiatry 1983; 44: 25-8
99. Akerstedt T. Do subjective sleep reports describe objective sleep? Insom 2003; 1: 11-6
100. Argyropoulos SV, Hicks JA, Nash JR, et al. Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Res 2003; 120: 179-90
101. Mayers AG, van Hooff JC, Baldwin DS. Quantifying subjective assessment of sleep and life-quality in antidepressant-treated depressed patients. Hum Psychopharmacol 2003; 18: 21-27
102. Oberndorfer S, Saletu-Zyhlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology 2000; 42: 69-81
103. Hutchinson DR, Tong S, Moon CA, et al. Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol 1992; 6 Suppl. 4: 43-51
104. Dorman T. Sleep and paroxetine: a comparison with mianserin in elderly depressed patients. Int Clin Psychopharmacol 1992; 6 Suppl. 4: 53-8
105. Satterlee WG, Faries D. The effects of fluoxetine on symptoms of insomnia in depressed patients. Psychopharmacol Bull 1995; 31: 227-37
106. Dossenbach M, Martenyi FS, De Verga E. Sleep quality during fluoxetine therapy in depression. Biol Psychiatry 1997; 42: S243
107. Stephenson DA, Harris B, Davies RH, et al. The impact of antidepressants on sleep and anxiety: a comparative study of fluoxetine and dothiepin using the Leeds Sleep Evaluation Questionnaire. Hum Psychopharmacol 2000; 15: 529-34
108. Rosenberg C, Damsbo N, Fuglum E, et al. Citalopram and imipramine in the treatment of depressive patients in general practice: a Nordic multicentre clinical study. Int Clin Psychopharmacol 1994; 9 Suppl. 1: 41-8
109. Bech P, Cialdella P. Citalopram in depression: meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 1992; 6 Suppl. 5: 45-54
110. Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8: 197-202
111. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995; 56: 229-37
112. Sechter D, Troy S, Paternetti S, et al. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 1999; 14: 41-8
113. Sogaard J, Lane R, Latimer P, et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 1999; 13: 406-14
114. Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151: 1069-72
115. Blacker R, Shanks NJ, Chapman N, et al. The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline. Psychopharmacology (Berl) 1988; 95 Suppl.: S18-24
116. Moon CA, Davey A. The efficacy and residual effects of trazodone (150mg nocte) and mianserin in the treatment of depressed general practice patients. Psychopharmacology (Berl) 1988; 95 Suppl.: S7-13
117. Guelfi JD, Ansseau M, Timmerman L, et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21: 425-31
118. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996; 57 Suppl. 2: 46-52
119. Manber R, Rush AJ, Thase ME, et al. The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. Sleep 2003; 26: 130-6
120. Buysse DJ, Reynolds III CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213
121. Nowell PD, Reynolds III CF, Buysse DJ, et al. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry 1999; 60: 89-95
122. Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology (Berl) 1999; 144: 220-33
123. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998; 13: 191-8
124. Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001; 62: 453-63
125. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002; 53 (1): 547-54
126. Nofzinger EA, Fasiczka A, Berman S, et al. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry 2000; 61 (11): 858-62
127. Cadilhac J. Tricyclics and REM sleep. In: Guilleminault C, Dement WC, Passouant P, editors. Narcolepsy. New York: Spectrum Publication, 1976: 605-23
128. Guilleminault C, Raynal D, Takahashi S, et al. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 1976; 54: 71-87
129. Schenck CH, Mahowald MW, Kim SW, et al. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep 1992; 15 (3): 226-35
130. Ellison JM, Stanziani P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 1993; 54 (11): 432-4
131. Wise M. Citalopram-induced bruxism [letter]. Br J Psychiatry 2001; 178: 182
132. Onofrj M, Luciano AL, Thomas A, et al. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology 2003; 60 (1): 113-5
133. Winkelman JW, James L. Serotonergic antidepressants are associated with REM sleep without atonia. Sleep 2004; 27 (2): 317-21
134. Pagel JF, Helfter P. Drug induced nightmares: an etiology based review. Hum Psychopharmacol 2003; 18 (1): 59-67
135. Lepkifker E, Dannon PN, Iancu I, et al. Nightmares related to fluoxetine treatment. Clin Neuropharmacol 1995; 18: 90-4
136. Markowitz JC. Fluoxetine and dreaming. J Clin Psychiatry 1991; 52 (10): 432
137. Koponen H, Lepola U, Leiononen E, et al. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiat Scand 1997; 96: 343-6
138. Kirschner NT, Medication and dreams: changes in dream content after drug treatment. Dreaming 1999; 9: 195-200
139. Pace-Schott EF, Gersh T, Silvestri R, et al. SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 2001; 10 (2): 129-42
140. Dilsaver SC, Greden JF, Antidepressant withdrawal phenomena. Biol Psychiatry 1984; 19 (2): 237-56
141. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39 (11): 1852-9
142. Vercoulen JH, Swanink CM, Zitman FG, et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996; 347 (9005): 858-61
143. Wilson SJ, Lillywhite AR, Potokar JP, et al. Adult night terrors and paroxetine. Lancet 1997; 350 (9072): 185
144. Bengtson H, Broman J-E, Hetta J. The effect of paroxetine on sleepwalking in 8 adults [abstract]. Sleep Res Online 1999; 2 Suppl. 1: 131
145. Smith IE, Quinnell TG. Pharmacotherapies for obstructive sleep apnoea: where are we now? Drugs 2004; 64 (13): 1385-99
146. Kopelman PG, Elliott MW, Simonds A, et al. Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. Int J Obes Relat Metab Disord 1992; 16 (10): 825-30
147. Kraiczi H, Hedner J, Dahlof P, et al. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 1999; 22 (1): 61-7
148. Hanzel DA, Proia NG, Hudgel DW. Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest 1991; 100 (2): 416-21
149. Evans JH. Evidence based management of nocturnal enuresis. BMJ 2001; 323 (7322): 1167-9
150. Radhakishun FS, van den Bos J, van der Heijden BC, et al. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 2000; 20 (5): 531-7
151. Thase ME, Fasiczka AL, Berman SR, et al. Electroencephalographic sleep profiles before and after cognitive behavior therapy of depression. Arch Gen Psychiatry 1998; 55 (2): 138-44